



How can genomics benefit your cancer patients?

Knowing a tumor's genetic fingerprint can aid in the diagnosis and prognosis of cancer and help inform treatment decisions.

Learn more about SearchLight DNA[™], an extensively validated diagnostic test from Vidium Animal Health[®] that uses next-generation sequencing to identify important mutations in 120 relevant cancer genes.


SearchLight DNA identifies important biomarkers to advance the care of pets with cancer





Discover how SearchLight DNA can provide insights into a cancer's origin, its behavior, and the optimal approach to treatment. How does SearchLight DNA[®] work?

Once your patient's tumor sample arrives at our genomics laboratory, Vidium scientists extract and sequence the DNA, and analyze each tumor's genome to identify its unique mutations. We then use our proprietary biomarker database, Vidium Insight[™], to bring the latest diagnostic, prognostic, and treatment guidance to each case.



Why run a tumor panel?

- :: Mutations in one tumor may not be present in another tumor of the same histology
- :: Most tumors evaluated by Vidium Insight have mutations with diagnostic, prognostic, and therapeutic actionability
- C ther tumors may have inferred actionability that can guide the use of targeted therapy

SearchLight DNA is backed by unimpeachable science

In a validation study, SearchLight DNA demonstrated:

- :: 95% sensitivity and 99% specificity for detection of low allele frequency (AF), single nucleotide variants (SNVs), and internal tandem duplications (ITDs)¹
- :: Reproducibility ≥95%¹
- :: Zero cross-contamination¹
- : High performance across tissue and tumor types¹





for detection of low AF SNVs and ITDs¹

5 THINGS TO KNOW ABOUT SEARCHLIGHT DNA

- 1. SearchLight DNA is a rigorously validated test.
- 2. As a descriptive panel, SearchLight DNA provides a new layer of comprehensive information about a pet's cancer so that *you* can make the best decisions for your patient and client.
- 3. SearchLight DNA is driven by our extensive database, Vidium Insight, which includes all the updated, curated, and pertinent information surrounding genomics in cancer, as well as extensive mutation data and clinical outcomes data.
- 4. Our in-house laboratory evaluates tumors without making assumptions on histology; genes and mutations are evaluated consistently.
- 5. Test results are summarized in a report highlighting the specific mutations found within that tumor.

When should you use SearchLight DNA[™]?

SearchLight DNA can be used for *any* case in which you and your client want all possible information on a tumor. This includes common canine cancers, such as mast cell tumors, lymphomas, and osteosarcomas. The test is also useful for identifying targeted therapy options for a particular case.

SEARCHLIGHT DNA IS PARTICULARLY USEFUL FOR THESE CASES

CASES	EXAMPLE
Poorly differentiated tumors	Undifferentiated round cell tumors
Tumors with an uncertain diagnosis	Amelanotic melanoma vs oral sarcoma
Tumors in uncommon locations	Mammary melanoma or retropharyngeal hemangiosarcoma
Tumors in which a standard of care does not currently exist	Splenic liposarcoma
Tumors in which there are no effective chemotherapy treatment options	Metastatic hemangiosarcoma
Tumors that have progressed despite standard-of-care treatment	Apocrine gland anal sac adenocarcinoma with local or distant progression
Metastatic lesions in unexpected or uncommon locations	Thyroid carcinoma that metastasized to the spleen
Pet owner preference	Pet owners who do not want to pursue injectable chemotherapy, preferring oral therapy options

Summary of relevant drug information to guide treatment

We collect all available information on any targeted drugs that match identified canine tumor mutations, including:

: Pharmacokinetics

Safety and/or dosing


:: Toxicology

: Drug resources

We also have strategic collaborations with institutions to conduct genomic and drug clinical trials.

Information on your patient's tumor is powered by Vidium Insight[™]

Vidium Insight is a proprietary knowledge database, combining extensive literature, mutation, and outcomes databases. To date, Vidium Insight has curated from...



...and these numbers will only increase!

What samples are needed to run a SearchLight DNA[™] test?

SearchLight DNA can be run on samples submitted in the following forms and quantities:

FINE-NEEDLE ASPIRATE (FNA) SAMPLES	
FNA SLIDES	>5 unstained or stained slides with 1 Diff-Quik slide
FNA LIQUID	>0.5 mL in sterile vial/tube with no additives
BIOPSY SAMPLES	
FFPE SCROLLS	10 x 10-micron sections with 1 adjacent H&E slide
UNSTAINED FFPE SLIDES	10 x 10-micron sections with 1 adjacent H&E slide
BONY TUMOR	Please submit a non-decalcified sample or allow us to coordinate with the pathology lab to select an appropriate sample.

FFPE = formalin-fixed, paraffin-embedded H&E = hematoxylin and eosin



What information is contained in a SearchLight DNA report?

Veterinarians who order SearchLight DNA will receive a complete report 9–12 days after the tumor sample arrives at our laboratory. Information contained in each report includes:

	n Vet Specialty + Emergency	Accession: V12345
Dr. Me	gan Howard	Page 148
		Research 42621 Reported 6731
-		
100	Molly David Work Canter	Anal An Ap Six Oxide:Oxide Penale 11y Long
9	Degrade Publishers Merceanitrone	
Search	Light DNA Overview	
linet	en biertified 4	Number of Clinical Trials:
1000	p.VeBDOlu	This Cancer Type: 3
943	Spike Sile	General Cancer 17
	Cipy Number Loss	
943	p.Arg208Cys	C 4 Daposto Bonates
-	Berlin .	2 Propriedic Biomatters
	ninanga pamagana	😥 2 Malshing Drugs Lapatinis, Neralinis
that hope	through participants	😥 2 Militing Drugs Lapatinis, Neralinis
-		•
Search	Light DNA Summary	
Search	ninopipene en sLight DNA Summary ostatel (20 units provide 10 May) beer sergin. The de subtrat former at 2020 Mariate along	ACCES 12 (2009) 121 - modeline was not detected indexiding that ACCES 12 (2009) 121 - modeline was not detected indexiding that ACCES 12 (2009) 121 - modeline was not detected in the control of the con
Search	ningipung an Light DNA Summary singit DI anny gene it May been sangle. To singit and an unser prime it May be stated as in or required in same primeray all because them, sugar	ARCA: 14,0000.142/modeline was not inferring industry that fairs of interactionary These DBMD and TMD alterations.
Search Search Notical a Inter the	mange pang ang kLight DNA Summury dialah sa sa dialah sa sa dialah sa sa dialah sa sa dialah sa sa dialah sa sa sa sa s	ACCES 12 (2009) 121 - modeline was not detected indexiding that ACCES 12 (2009) 121 - modeline was not detected indexiding that ACCES 12 (2009) 121 - modeline was not detected in the control of the con
Search Internet Internet Internet Internet Internet Internet Internet Internet	nicesprene real Light DNA Summary volunted Drawing provide Mark to know angle. The the order of program to RAN's to desire at least regeleted and a provide state of the second of the RANG data know and a Mark to second on Cardy its PDB option and a distantion has been a manufac- gaphic for the second of the second of the second of Cardy its PDB option and a distantion has been assessed applies for the second of the sec	ANDER 13 (2007) 13 (Variante na march advance) a declare final and a characterize programme (2007) a declaration (1) of the photogen decayware. In a marchine the lacest characterize provided and all we wanders the lacest characterize provided and in a soft wanders to Transitivity.
Search Search Search Solar Sea Solar Sea Solar Sea Solar Sea Solar Sea	ninangiones ene SLIGHE DINA Summary in a solar of the second se	ANDER SUGGERS (S) makes and second advanced in the second advanced into
Search Search Search Search Solar Unit Search Solar Sea Search Solar Sea Search	Standard and St	MADE VALUES (LA INVESTIGATION DE LA INVESTIGATIONE DELLA INVESTIGATIONE DELLA INVESTIGATIONE DELLA INVESTIGATIONE DE LA INVESTIGATIONE DELLA INVESTI
Search Search Notice in Adde Unit Adde Unit Ad	Light DNA Summary solution (3) earning provide May be loss series). The solution (3) earning provide May be loss series). The solution (3) earning and the solution of the solution operation and any plantesized provide many solution operation and any plantesized provide many solution (and the SNR (and how one)). The solution is have an exception of the solution of the solution of the solution on a solution and solution and solution of the solution on a solution of the solution of the solution of the solution on a solution of the solution of the solution of the solution on a solution of the solutio	ACCO 10.0007.13 (matter any or defaults) indexing the according to the second
Search Search No. teal o Adde the Adde	Light DNA Summary solution (3) earning provide May be loss series). The solution (3) earning provide May be loss series). The solution (3) earning and the solution of the solution operation and any plantesized provide many solution operation and any plantesized provide many solution (and the SNR (and how one)). The solution is have an exception of the solution of the solution of the solution on a solution and solution and solution of the solution on a solution of the solution of the solution of the solution on a solution of the solution of the solution of the solution on a solution of the solutio	NEXT (3,000) Summaria wan wat wat dening the sector of the
Search Search No. teal o Adde the Adde	A Light DNA Summary A Light DNA Summary the device of the second secon	NEXT (3,000) Summaria wan wat wat dening the sector of the
Search Search No. teal o Adde the Adde	A Light DNA Summary A Light DNA Summary the device of the second secon	NEXT (3,000) Summaria wan wat wat dening the sector of the

- :: Genomic mutation information, including diagnostic, prognostic, and therapeutic biomarkers
- :: A list of targeted therapeutic drug(s), if the patient's tumor mutations are a match for an existing drug
- : Pharmacologic marker (MDR1) mutation status with gene summary
- Clinical trials available for the patient's cancer type
- :: References
- : Assay description and genes/mutations evaluated

Discover all of Antech's innovative diagnostic solutions and services. HONG KONG +852 2371 0080 SINGAPORE +65 6291 5412 VISIT avd.asia

